It is cost-effective only for infants at high risk of hospitalization, including those with the following characteristics: < 1 year old with hemodynamically significant congenital heart disease < 1 year old with chronic lung disease of prematurity (gestational age < 32 weeks and 0 days with the need for oxygen therapy for at least 28 days after birth) Born at < 29 weeks gestation and are < 1 year old at the start of RSV season Chronic lung disease of prematurity in the second year of life and have received within 6 months of RSV season treatment with chronic corticosteroids or diuretics or have had a continued need for oxygen therapy Prophylaxis may also be considered for Infants in the first year of life who have anatomic pulmonary abnormalities that impair the ability to effectively clear the upper airways Infants who have neuromuscular disorders Children < 24 months old who have profound immunocompromise The dose of palivizumab is 15 mg / kg IM.